Protalix BioTherapeutics (PLX) Share-based Compensation (2010 - 2026)
Protalix BioTherapeutics (PLX) posted quarterly Share-based Compensation of $532000.0 for Q1 2026, up 1512.12% year-over-year from $33000.0 in Q1 2025, and down 67.16% quarter-over-quarter from $1.6 million in Q4 2025.
Protalix BioTherapeutics (PLX) Share-based Compensation (2010 - 2026) Analysis & Trends
Protalix BioTherapeutics' Share-based Compensation history runs 17 years deep, the most recent figure standing at $532000.0 for Q1 2026.
- In Q1 2026, Share-based Compensation rose 1512.12% year-over-year to $532000.0; the TTM figure through Mar 2026 stood at $3.7 million (up 18.84% YoY), while the FY2025 annual figure was $3.2 million, down 2.09% from the prior year.
- Share-based Compensation for Q1 2026 stood at $532000.0, down from $1.6 million in the prior quarter.
- The five-year high for Share-based Compensation was $2.9 million in Q4 2024, with the low at -$1.6 million in Q3 2024.
- The 5-year median for Share-based Compensation is $335000.0 (2022), against an average of $550625.0.
- The sharpest annual moves came in 2024 and 2026: Share-based Compensation tumbled 322.64% in 2024, then jumped 1512.12% in 2026.
- Protalix BioTherapeutics' Share-based Compensation stood at $398000.0 in 2022, then slumped by 229.15% to -$514000.0 in 2023, then surged by 659.73% to $2.9 million in 2024, then sank by 43.69% to $1.6 million in 2025, then slumped by 67.16% to $532000.0 in 2026.
- Business Quant data shows PLX's Share-based Compensation at $532000.0 in Q1 2026, $1.6 million in Q4 2025, and $1.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 86.63 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 41.25 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 28.05 Mn |
| 10 | Protalix BioTherapeutics | 190.37 Mn | 149.71 Mn | 12.13 Mn | 398,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 398,000.00 |
| Jun 30, 2026 | 398,000.00 |
| Mar 31, 2026 | 532,000.00 |
| Mar 31, 2026 | 532,000.00 |
| Dec 31, 2025 | 1.62 Mn |
| Dec 31, 2025 | 1.62 Mn |
| Sep 30, 2025 | 1.53 Mn |
| Sep 30, 2025 | 1.53 Mn |
| Mar 31, 2025 | 33,000.00 |
| Mar 31, 2025 | 33,000.00 |
| Dec 31, 2024 | 2.88 Mn |
| Dec 31, 2024 | 2.88 Mn |
| Sep 30, 2024 | -1.60 Mn |
| Sep 30, 2024 | -1.60 Mn |
| Jun 30, 2024 | 1.79 Mn |
| Jun 30, 2024 | 1.79 Mn |
| Mar 31, 2024 | 186,000.00 |
| Mar 31, 2024 | 186,000.00 |
| Dec 31, 2023 | -514,000.00 |
| Dec 31, 2023 | -514,000.00 |